{"transactions":[{"id":3530070,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":157680,"kind":"organization","name":"Aperture Venture Partners IV, L.P.","position":1,"cik":"0001659119","reported_name":"Aperture Venture Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157681,"kind":"organization","name":"Aperture Ventures IV Management, LLC","position":2,"cik":"0001775271","reported_name":"Aperture Ventures IV Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-05-13T17:01:17.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":2054795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":232963},"source":{"system":"sec-edgar","filing":"0000899243-19-013254","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1775271/000089924319013254/doc4.xml","form_type":"4"}},{"id":3530069,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":157680,"kind":"organization","name":"Aperture Venture Partners IV, L.P.","position":1,"cik":"0001659119","reported_name":"Aperture Venture Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157681,"kind":"organization","name":"Aperture Ventures IV Management, LLC","position":2,"cik":"0001775271","reported_name":"Aperture Ventures IV Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T17:01:17.000Z","date":"2019-05-09","kind":"purchase","acquired":true,"shares":112000,"price":10,"value":1120000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P."}],"balance_after":344963,"source":{"system":"sec-edgar","filing":"0000899243-19-013254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1775271/000089924319013254/doc4.xml","form_type":"4"}},{"id":3530068,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":157680,"kind":"organization","name":"Aperture Venture Partners IV, L.P.","position":1,"cik":"0001659119","reported_name":"Aperture Venture Partners IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157681,"kind":"organization","name":"Aperture Ventures IV Management, LLC","position":2,"cik":"0001775271","reported_name":"Aperture Ventures IV Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T17:01:17.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":232963,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P."}],"balance_after":232963,"source":{"system":"sec-edgar","filing":"0000899243-19-013254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1775271/000089924319013254/doc4.xml","form_type":"4"}}]}